Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Epilepsy study aims to predict who will respond to treatment

NCT ID NCT05374928

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study followed 316 people with idiopathic generalized epilepsy, including those newly diagnosed and those already known to respond or not respond to treatment. Researchers collected data from seizure diaries, fitness trackers, quality-of-life surveys, and cognitive tests, along with genetic and microbiome samples. The goal was to identify biomarkers that could predict how well someone will respond to epilepsy treatments, helping patients make informed decisions about driving, work, and family planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could identify biological markers that help doctors predict how well a person with generalized epilepsy will respond to treatment, leading to more personalized care.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. The findings may take years to translate into clinical practice and might not apply to all epilepsy types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

316 people

The number who actually took part.

Started

Mar 2020

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with newly diagnosed IGE, as well as a cohort of subjects with established IGE.

Ages

13 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohort 1: Newly Diagnosed IGE Inclusion criteria: 1. Age ≥13 years at time of enrollment 2. Age ≥8 years at time of seizure onset 3. Clinical seizure(s) and history consistent with IGE. The only permitted seizure types are absence, myoclonus or generalized tonic-clonic convulsions 4. Occurrence of at least 1 seizure of any type in the 6 months prior to treatment 5. Patients must have one of the following: * GTCSs alone accompanied by generalized spike-wave consistent with IGE per adjudication review * GTCSs with a history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review * GTCSs associated with a history of absence and/or myoclonus, not accompanied by generalized spike-wave consistent with IGE per adjudication review * A clear history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review 6. Availability of a complete medication history since initiation of treatment, including doses and date of initiation 7. No competing cause of epilepsy (e.g. traumatic brain injury) 8. AED treatment (for seizures) instituted not more than 12 months before enrollment Exclusion Criteria 1. Focal epilepsy 2. Generalized/focal epilepsy mixed syndromes 3. Progressive neurological disorder (brain tumor, Alzheimer's disease, progressive myoclonic epilepsy, etc.) 4. Epileptic or developmental encephalopathy 5. Major medical co-morbidities (e.g. renal failure requiring dialysis, metastatic cancer, HIV, or significant liver or renal disease) 6. Autism Spectrum Disorder 7. History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years 8. Seizures only during pregnancy 9. History of previous or current significant psychiatric disorder that would interfere with study requirements Cohort 2: Longstanding Treatment Responsive Inclusion Criteria: 1. Age ≥13 years at time of enrollment 2. Age ≥8 years at time of seizure onset 3. Clinical seizure(s) and history consistent with IGE. The only permitted seizure types are absence, myoclonus or generalized tonic-clonic convulsions 4. Patients must have had one of the following: 1. GTCSs alone accompanied by generalized spike-wave consistent with IGE per adjudication review 2. GTCSs with a history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review 3. GTCSs associated with a history of absence and/or myoclonus, not accompanied by generalized spike-wave consistent with IGE per adjudication review 4. A clear history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review 5. Availability of a complete medication history since initiation of treatment, including doses and date of initiation 6. No competing cause of epilepsy (e.g. traumatic brain injury) 7. Two years of well-controlled seizures. 1. No convulsive seizures in the last two years 2. Myoclonic or absence seizures must be rare (\<2 per year) and non-disabling 3. Ongoing therapy with \> 1 antiseizure medication Exclusion Criteria: 1. Focal epilepsy 2. Paroxysmal nonepileptic seizures 3. Generalized/focal epilepsy mixed syndromes 4. Progressive neurological disorder (brain tumor, Alzheimer's disease, progressive myoclonic epilepsy, etc.) 5. Epileptic or developmental encephalopathy 6. Major medical co-morbidities (e.g. renal failure requiring dialysis, metastatic cancer, HIV, or significant liver or renal disease) 7. Autism Spectrum Disorder 8. History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years 9. Seizures only during pregnancy 10. History of previous or current significant psychiatric disorder that would interfere with study requirements Cohort 3: Longstanding IGE, Treatment Resistant Inclusion Criteria: 1. Age ≥13 years at time of enrollment 2. Age ≥8 years at time of seizure onset 3. Clinical seizure(s) and history consistent with IGE. The only permitted seizure types are absence, myoclonus or generalized tonic-clonic convulsions 4. Occurrence of at least 1 seizure of any type in the 6 months prior to treatment onset 5. Patients must have had one of the following: 1. GTCSs alone accompanied by generalized spike-wave consistent with IGE per adjudication review 2. GTCSs with a history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review 3. GTCSs associated with a history of absence and/or myoclonus, not accompanied by generalized spike-wave consistent with IGE per adjudication review 4. A clear history of absence and/or myoclonus, accompanied by generalized spike-wave consistent with IGE per adjudication review 6. Availability of a complete medication history since initiation of treatment. This should include doses and date of initiation if possible, but minimum information would include name of drug, approximate duration of administration and reason for discontinuation, if applicable. 7. No competing cause of epilepsy (e.g. traumatic brain injury) 8. Treatment resistant IGE 1. Initiation of treatment at least 2 years prior to enrollment 2. Treatment resistance, as defined by failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination to achieve seizure freedom). ASMs taken at enrollment would count towards this minimum. 3. Either or both of the following two: i. One GTCC per year over the last 2 years. ii. Any type of seizure at least every 3 months which can consist of either: disabling myoclonus or absence (in the opinion of the subject and investigator) or GTCC d. Such seizures were not primarily due to significant illness (e.g, URI is not significant unless temperature \>101oF (38.3oC), nonadherence to antiseizure medications or \>2 alcoholic beverages within 48 hrs of seizure e. Ongoing therapy with \> 1 antiseizure medication Exclusion Criteria: 1. Focal epilepsy 2. Paroxysmal nonepileptic seizures 3. Generalized/focal epilepsy mixed syndromes 4. Progressive neurological disorder (brain tumor, Alzheimer's disease, progressive myoclonic epilepsy, etc.) 5. Epileptic or developmental encephalopathy 6. Major medical co-morbidities (e.g. renal failure requiring dialysis, metastatic cancer, HIV, or significant liver or renal disease) 7. Autism Spectrum Disorder 8. History of chronic drug or alcohol abuse (misuse or excessive use that interferes with activities of daily living) within the last 2 years 9. Seizures only during pregnancy 10. History of previous or current significant psychiatric disorder that would interfere with study requirements 11. History of/suspicion of provoked seizures accounting for 25% or more of seizures over the prior 2 years (eg alcohol, non-adherence, significant sleep deprivation).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic generalized epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Georgetown University

    Washington D.C., District of Columbia, 20057, United States

  • Maine Medical Center

    Portland, Maine, 04102, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Mid-Atlantic Epilepsy Sleep Center

    Bethesda, Maryland, 20817, United States

  • Minnesota Epilepsy Group

    Saint Paul, Minnesota, 55113, United States

  • Monash University

    Melbourne, Clayton VIC, 3800, Australia

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • NYU Langone Health - Comprehensive Epilepsy Center (CEC)

    New York, New York, 10016, United States

  • Northwell Health

    New York, New York, 10065, United States

  • St. Barnabas Medical Center

    Livingston, New Jersey, 07039, United States

  • The Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • University of California San Francisco (UCSF)

    San Francisco, California, 94143, United States

  • University of Miami

    Miami, Florida, 33146, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Texas Health Science Center

    San Antonio, Texas, 77030, United States

  • University of Utah Hospital

    Salt Lake City, Utah, 84132, United States

  • Washington University

    St Louis, Missouri, 63130, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.